Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to -$34000.0.

  • vTv Therapeutics' Gains from Investment Securities fell 1333.33% to -$34000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $87000.0, marking a year-over-year increase of 19886.36%. This contributed to the annual value of $100000.0 for FY2024, which is 9764.43% down from last year.
  • Per vTv Therapeutics' latest filing, its Gains from Investment Securities stood at -$34000.0 for Q3 2025, which was down 1333.33% from -$34000.0 recorded in Q2 2025.
  • vTv Therapeutics' Gains from Investment Securities' 5-year high stood at $7.1 million during Q4 2021, with a 5-year trough of -$34000.0 in Q2 2025.
  • For the 5-year period, vTv Therapeutics' Gains from Investment Securities averaged around $2.0 million, with its median value being $188000.0 (2024).
  • In the last 5 years, vTv Therapeutics' Gains from Investment Securities skyrocketed by 7207.98% in 2021 and then tumbled by 10069.61% in 2024.
  • Over the past 5 years, vTv Therapeutics' Gains from Investment Securities (Quarter) stood at $7.1 million in 2021, then plummeted by 97.17% to $200000.0 in 2022, then soared by 2055.0% to $4.3 million in 2023, then tumbled by 95.64% to $188000.0 in 2024, then tumbled by 118.09% to -$34000.0 in 2025.
  • Its Gains from Investment Securities was -$34000.0 in Q3 2025, compared to -$34000.0 in Q2 2025 and -$33000.0 in Q1 2025.